| Baseline albuminuria predicts the efficacy of blood pressure-lowering drugs in preventing cardiovascular events. | |
| | |
MedLine Citation:
|
PMID: 18241288 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: Albuminuria has been proven to be associated with cardiovascular morbidity and mortality. Such an association has been found not only in subjects with diabetes and hypertension, but also in the general population. It could therefore be expected that especially subjects with higher albuminuria levels may benefit from blood pressure-lowering agents to improve their cardiovascular outcome. WHAT THIS STUDY ADDS: This study indicates that the efficacy of blood pressure-lowering agents to prevent cardiovascular events is dependent of the level of albuminuria before start of such treatment. The higher baseline albuminuria, the better the relative and absolute risk reduction for cardiovascular events with blood pressure-lowering drugs. The data also suggest a possible better cardiovascular protective effect of renin-angiotensin intervening agents compared with other blood pressure-lowering agents. AIMS: Albuminuria has been proven to be associated with cardiovascular (CV) events in specific patient populations, but also in the general population. This study aimed to investigate whether the efficacy of blood pressure-lowering agents in preventing CV events depends on baseline urinary albumin excretion (UAE) and, if so, whether this holds true for blood pressure-lowering agents in general, or is limited to agents that interfere in the renin-angiotensin system. METHODS: Data were used from a community-based cohort study and pharmacy dispensing records. Included were subjects with hypertension (systolic blood pressure >or=140 and/or diastolic blood pressure >or=90 mmHg), no cardiovascular disease history, and no previous use of blood pressure-lowering agents. RESULTS: During study follow-up (7.1 +/- 1.6 years), 122 CV events were observed in 1185 subjects included. Start of blood pressure-lowering agents vs. non-use was associated with a difference in absolute CV event risk of 0.7%, 6% and 12.6% for all subjects, those with UAE >or= 15 mg day(-1) and >or=30 mg day(-1), respectively. Cox regression analysis showed that the relative risk for CV events after start of blood pressure-lowering agents was significantly dependent (P < 0.05) on baseline UAE; with hazard ratios of 0.87 [95% confidence interval (CI) 0.48, 1.60, P = NS], 0.58 (95% CI 0.36, 0.94, P < 0.05) and 0.37 (95% CI 0.20, 0.68, P < 0.05), for subjects with UAE < 15, >or=15 and >or=30 mg day(-1), respectively. Results adjusted for covariates were essentially similar. The use of angiotensin converting enzyme inhibitor/angiotensin-II receptor blocker (ACEi/ARB) treatment tended to be associated with a more favourable CV prognosis when compared with non-ACEi/ARB treatment (difference P = 0.06). CONCLUSIONS: Our results suggest that the efficacy of blood pressure-lowering agents to prevent CV events is dependent on baseline albuminuria. The higher baseline albuminuria, the more absolute as well as relative risk reduction can be achieved. Our data suggest that this may especially be true for ACEi/ARBs. We caution that this is an observational study, and that these conclusions should therefore be regarded as hypothesis generating, rather than hypothesis testing. |
| | |
Authors:
|
Cornelis Boersma; Maarten J Postma; Sipke T Visser; Jarir Atthobari; Paul E de Jong; Lolkje T W de Jong-van den Berg; Ron T Gansevoort; |
Related Documents
:
|
15485398 - Proteinuria and hypertensive nephrosclerosis in african americans. 20956208 - Acetaminophen increases blood pressure in patients with coronary artery disease. 8524498 - Prevalence of micro- and macroalbuminuria and their relationship with other cardiovascu... 20711758 - Hypertension in the elderly: what is the goal blood pressure target and how can this be... 2388158 - Heart rate and arterial blood pressure at the onset of static exercise in man with comp... 2048368 - Effects of a screening program for hypertension in a community. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2008-01-30 |
Journal Detail:
|
Title: British journal of clinical pharmacology Volume: 65 ISSN: 1365-2125 ISO Abbreviation: Br J Clin Pharmacol Publication Date: 2008 May |
Date Detail:
|
Created Date: 2008-04-23 Completed Date: 2008-07-23 Revised Date: 2012-09-10 |
Medline Journal Info:
|
Nlm Unique ID: 7503323 Medline TA: Br J Clin Pharmacol Country: England |
Other Details:
|
Languages: eng Pagination: 723-32 Citation Subset: IM |
Affiliation:
|
Groningen Research Institute of Pharmacy (GRIP), University of Groningen, Groningen, The Netherlands. c.boersma@rug.nl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Albuminuria / etiology* Antihypertensive Agents / therapeutic use* Blood Pressure / drug effects* Cardiovascular Diseases / prevention & control*, urine Female Follow-Up Studies Humans Male Middle Aged Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents |
| Comments/Corrections | |
Comment In:
|
Nat Clin Pract Nephrol. 2008 Aug;4(8):414-5
[PMID:
18578007
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population.
Next Document: Maternal chronic hepatitis B virus does not affect neonatal biotinidase activity.